Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q4 EPS by 16c

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q4 EPS of $0.07, $0.16 worse than the analyst estimate of $0.23. Revenue for the quarter came in at $108.45 million versus the consensus estimate of $106.96 million.

For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.

You May Also Be Interested In

• Broadcom credit risk measures rise amid AI financing deals
• Freedom Broker Starts Citizens Inc. (CIA) at Buy
• NAPCO Security Tech (NSSC) Tops Q4 EPS by 11c